Products for Research Use Only
RegisterLogin

E6201

CAT: 0804-HY-15496Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15496Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC50 value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC50 value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC50 value of 19 nM. Anti-tumor and anti-psoriasis efficacy[1][2].
CAS Number
603987-35-5
Product Name Alternative
ER-806201
UNSPSC
12352005
Target
FLT3; MEK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/e6201.html
Solubility
10 mM in DMSO
Smiles
OC1=C2C(/C=C/C[C@@H]([C@@H](C(/C=C\[C@H]([C@@H](OC2=O)C)C)=O)O)O)=CC(NCC)=C1
Molecular Formula
C21H27NO6
Molecular Weight
389.44
References & Citations
[1]Masaki Goto, et al. E6201 [ (3S,4R,5Z,8S,9S,11E) -14- (ethylamino) -8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7 (8H) -dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) -1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. J Pharmacol Exp Ther. 2009 Nov;331 (2) :485-95.|[2]Jangsoon Lee, et al. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun;175 (2) :339-351.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
MEK1

Alternative Products

CatalogName
MBS5804454E6201

Popular Products